Search results for Frovocimab

Frovocimab Biosimilar – Anti-PCSK9 mAb – Research Grade, ProteoGenix, PX-TA1527

Description of Frovocimab Biosimilar - Anti-PCSK9 mAb - Research Grade Introduction Frovocimab Biosimilar, also known as Anti-PCSK9 mAb, is a research grade antibody that has shown promising results in the treatment of various diseases. This article will provide a comprehensive description of the structure, activity, and potential applications of this novel therapeutic target. Structure of Frovocimab Biosimilar Frovocimab Biosimilar is a monoclonal antibody (mAb) that specifically targets PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein involved in the regulation of cholesterol levels in the body. It is a fully humanized IgG1 antibody, meaning it is derived from human genes and has a similar structure to natural antibodies produced by the body. The antibody consists of two heavy chains and two light chains, connected by disulfide bonds. The variable regions of the antibody, responsible for binding to PCSK9, are located at the tips of the heavy and light chains. This unique structure allows the antibody to specifically bind to PCSK9 and inhibit its activity. Activity of Frovocimab Biosimilar Frovocimab Biosimilar works by blocking the interaction between PCSK9 and the LDL receptor (LDLR). PCSK9 normally binds to the LDLR and targets it for degradation, leading to increased levels of LDL cholesterol in the blood. By inhibiting this interaction, Frovocimab Biosimilar increases the number of LDLRs on the surface of cells, resulting in increased clearance of LDL cholesterol from the blood. In addition, Frovocimab Biosimilar has been shown to reduce the production of PCSK9 by liver cells, further decreasing the levels of LDL cholesterol in the blood. This dual mechanism of action makes Frovocimab Biosimilar a highly effective therapeutic target for lowering LDL cholesterol levels. Applications of Frovocimab Biosimilar Frovocimab Biosimilar has shown promising results in the treatment of various diseases related to high levels of LDL cholesterol, including familial hypercholesterolemia and atherosclerosis. It has also been studied as a potential treatment for other conditions such as non-alcoholic fatty liver disease and type 2 diabetes. In addition, Frovocimab Biosimilar has the potential to be used in combination with other lipid-lowering therapies, such as statins, to further reduce LDL cholesterol levels. This makes it a valuable addition to the current treatment options for patients with high cholesterol levels. Conclusion In summary, Frovocimab Biosimilar is a promising therapeutic target for the treatment of diseases related to high levels of LDL cholesterol. Its unique structure and dual mechanism of action make it a highly effective antibody for inhibiting the activity of PCSK9 and lowering LDL cholesterol levels. Further research and clinical trials are needed to fully explore the potential applications of this novel antibody in the treatment of various diseases.

Frovocimab, Abbexa, abx831487

Frovocimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PCSK9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Antibody drugs targeting PCSK9 targets.

Frovocimab ELISA Kit, ProteoGenix, KPTX268

Description of Frovocimab ELISA Kit Introduction Frovocimab is a novel monoclonal antibody that has shown promising results in preclinical studies as a potential therapeutic agent for the treatment of various diseases. It specifically targets a protein known as human leukocyte antigen-E (HLA-E), which plays a crucial role in immune regulation and has been implicated in the development of several diseases. In order to facilitate the detection and quantification of Frovocimab in biological samples, a Frovocimab ELISA (enzyme-linked immunosorbent assay) kit has been developed. Structure of Frovocimab Frovocimab is a fully humanized IgG1 monoclonal antibody, meaning that it is derived from human cells and has a similar structure to naturally occurring antibodies in the body. It consists of two identical heavy chains and two identical light chains, connected by disulfide bonds. The variable regions of the antibody, responsible for binding to its target, are located at the tips of the two arms of the Y-shaped structure. The constant regions of the antibody are responsible for mediating effector functions, such as activation of the immune system. Activity of Frovocimab Frovocimab specifically binds to HLA-E with high affinity, inhibiting its interaction with natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). This leads to the suppression of immune responses, making it a potential therapeutic agent for diseases where an overactive immune response is detrimental. In addition, Frovocimab has been shown to induce antibody-dependent cellular cytotoxicity (ADCC), where immune cells are activated to attack and kill cells that are bound by the antibody. This dual mechanism of action makes Frovocimab a promising candidate for the treatment of various diseases. Application of Frovocimab ELISA Kit The Frovocimab ELISA kit is a valuable tool for the detection and quantification of Frovocimab in biological samples. It is designed to be highly sensitive, specific, and easy to use. The kit contains all the necessary components, including pre-coated plates, standards, controls, and detection reagents, for the accurate measurement of Frovocimab levels in samples such as serum, plasma, and cell culture supernatant. The assay principle of the Frovocimab ELISA kit is based on the sandwich enzyme immunoassay technique. In this assay, Frovocimab is first captured by the immobilized anti-human IgG antibody on the plate. Then, a detection antibody specific for Frovocimab is added, followed by a secondary enzyme-conjugated antibody. The amount of Frovocimab present in the sample is directly proportional to the color intensity produced by the enzyme reaction, which can be measured using a spectrophotometer. The Frovocimab ELISA kit has a wide range of applications, including pharmacokinetic studies, clinical trials, and research on the mechanism of action of Frovocimab. It can also be used to monitor Frovocimab levels during treatment, helping to optimize dosing regimens and assess patient response. Conclusion In summary, Frovocimab is a promising therapeutic antibody that targets HLA-E and has the potential to treat a variety of diseases. The development of the Frovocimab ELISA kit provides a valuable tool for the detection and quantification of this antibody in biological samples, facilitating its use in clinical and research settings. Further studies and clinical trials are needed to fully understand the potential of Frovocimab as a therapeutic agent.

Frovocimab ELISA Kit, Abbexa, abx395157

Frovocimab ELISA Kit is a quantitative ELISA kit for detection of Frovocimab.Frovocimab (LY3015014) (INN) is a monoclonal antibody designed for the treatment of hypercholesterolemia.This drug is being developed by Eli Lilly and Company.

Frovocimab Biosimilar - Research Grade, ichor.bio, ICH5558

Research Grade Frovocimab (HV275036), abinScience, HV275036